» Articles » PMID: 20116985

Regulation of CD4 T Cell Activation and Effector Function by Inducible Costimulator (ICOS)

Overview
Publisher Elsevier
Date 2010 Feb 2
PMID 20116985
Citations 104
Authors
Affiliations
Soon will be listed here.
Abstract

Inducible costimulator (ICOS), a member of the CD28 family of costimulatory molecules, is upregulated on the surface of T cells following T cell activation and upon binding to its ligand (ICOSL), initiates a cascade of events that can shape key aspects of the immune response. Although initial studies focused on determining the role of ICOS in Th1 versus T helper 2 (Th2) responses, new insights into its biology have revealed the contribution of ICOS to germinal center formation and isotype switching, as well as its relevance to the fate and function of effector and regulatory CD4(+) T cells in the response against self (i.e., tumors) and non-self (i.e., bacterial, worm, and viral infections). This multiplicity of roles positions ICOS at the center of attention for immunotherapy where manipulation of this pathway could lead to novel approaches in the treatment of human diseases.

Citing Articles

Transcriptome combined with single-cell sequencing explored prognostic markers associated with T cell exhaustion characteristics in head and neck squamous carcinoma.

Liu J, Li P, Zhang Y, Zheng L Sci Rep. 2025; 15(1):8209.

PMID: 40065044 PMC: 11893791. DOI: 10.1038/s41598-025-91299-z.


Longitudinal single cell profiling of epitope specific memory CD4+ T cell responses to recombinant zoster vaccine.

Wen X, Hu A, Presnell S, Ford E, Koelle D, Kwok W Nat Commun. 2025; 16(1):2332.

PMID: 40057520 PMC: 11890790. DOI: 10.1038/s41467-025-57562-7.


Migration arrest and transendothelial trafficking of human pathogenic-like Th17 cells are mediated by differentially positioned chemokines.

Parween F, Singh S, Kathuria N, Zhang H, Ashida S, Otaizo-Carrasquero F Nat Commun. 2025; 16(1):1978.

PMID: 40000641 PMC: 11861662. DOI: 10.1038/s41467-025-57002-6.


ICOS-expressing CAR-T cells mediate durable eradication of triple-negative breast cancer and metastasis.

Cao L, Peng H, Chen Y, Xia B, Zeng T, Guo J J Immunother Cancer. 2024; 12(11).

PMID: 39532433 PMC: 11555110. DOI: 10.1136/jitc-2024-010028.


Immune checkpoint inhibitors in infectious disease.

King H, Lewin S Immunol Rev. 2024; 328(1):350-371.

PMID: 39248154 PMC: 11659942. DOI: 10.1111/imr.13388.